Cargando…

Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021

Pediatric tinea capitis displays a wide range of prevalence, with significant variability among populations. We retrospectively extracted the medical records of 456 pediatric patients diagnosed with tinea capitis during the years 2010–2021, from the dermatology outpatient clinics in two tertiary med...

Descripción completa

Detalles Bibliográficos
Autores principales: Dascalu, Joel, Zaaroura, Hiba, Renert-Yuval, Yael, Khamaysi, Ziyad, Avitan-Hersh, Emily, Friedland, Rivka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054890/
https://www.ncbi.nlm.nih.gov/pubmed/36983534
http://dx.doi.org/10.3390/jof9030366
_version_ 1785015780791812096
author Dascalu, Joel
Zaaroura, Hiba
Renert-Yuval, Yael
Khamaysi, Ziyad
Avitan-Hersh, Emily
Friedland, Rivka
author_facet Dascalu, Joel
Zaaroura, Hiba
Renert-Yuval, Yael
Khamaysi, Ziyad
Avitan-Hersh, Emily
Friedland, Rivka
author_sort Dascalu, Joel
collection PubMed
description Pediatric tinea capitis displays a wide range of prevalence, with significant variability among populations. We retrospectively extracted the medical records of 456 pediatric patients diagnosed with tinea capitis during the years 2010–2021, from the dermatology outpatient clinics in two tertiary medical centers. Three species were isolated in 90% of patients: T. tonsurans, M. canis, and T. violaceum. While T. tonsurans presented a six-fold increase in incidence during the years 2019–2021, M. canis maintained stable incidence rates. Furthermore, terbinafine was the most efficient antifungal agent against T. tonsurans, achieving complete clinical clearance in 95% of patients, as compared to fluconazole (68%) and griseofulvin (38%) (p < 0.001). The mycological cure was recorded in 61/90 (68%) of patients with available data, at an average of 10 weeks. For patients with M. canis, griseofulvin and fluconazole were equally efficient (73% and 66%, respectively) (p = 0.44). Kerion was described in 36% and 14% of patients with T. tonsurans and M. canis, respectively, (p < 0.001). In conclusion, since 2019, there has been a significant increase in the prevalence of T. tonsurans, establishing this pathogen as the most common cause for tinea capitis in our population. Our data suggest that terbinafine is effective and presents high cure rates for tinea capitis in the pediatric population.
format Online
Article
Text
id pubmed-10054890
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100548902023-03-30 Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021 Dascalu, Joel Zaaroura, Hiba Renert-Yuval, Yael Khamaysi, Ziyad Avitan-Hersh, Emily Friedland, Rivka J Fungi (Basel) Article Pediatric tinea capitis displays a wide range of prevalence, with significant variability among populations. We retrospectively extracted the medical records of 456 pediatric patients diagnosed with tinea capitis during the years 2010–2021, from the dermatology outpatient clinics in two tertiary medical centers. Three species were isolated in 90% of patients: T. tonsurans, M. canis, and T. violaceum. While T. tonsurans presented a six-fold increase in incidence during the years 2019–2021, M. canis maintained stable incidence rates. Furthermore, terbinafine was the most efficient antifungal agent against T. tonsurans, achieving complete clinical clearance in 95% of patients, as compared to fluconazole (68%) and griseofulvin (38%) (p < 0.001). The mycological cure was recorded in 61/90 (68%) of patients with available data, at an average of 10 weeks. For patients with M. canis, griseofulvin and fluconazole were equally efficient (73% and 66%, respectively) (p = 0.44). Kerion was described in 36% and 14% of patients with T. tonsurans and M. canis, respectively, (p < 0.001). In conclusion, since 2019, there has been a significant increase in the prevalence of T. tonsurans, establishing this pathogen as the most common cause for tinea capitis in our population. Our data suggest that terbinafine is effective and presents high cure rates for tinea capitis in the pediatric population. MDPI 2023-03-17 /pmc/articles/PMC10054890/ /pubmed/36983534 http://dx.doi.org/10.3390/jof9030366 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dascalu, Joel
Zaaroura, Hiba
Renert-Yuval, Yael
Khamaysi, Ziyad
Avitan-Hersh, Emily
Friedland, Rivka
Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021
title Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021
title_full Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021
title_fullStr Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021
title_full_unstemmed Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021
title_short Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021
title_sort pediatric tinea capitis: a retrospective cohort study from 2010 to 2021
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054890/
https://www.ncbi.nlm.nih.gov/pubmed/36983534
http://dx.doi.org/10.3390/jof9030366
work_keys_str_mv AT dascalujoel pediatrictineacapitisaretrospectivecohortstudyfrom2010to2021
AT zaarourahiba pediatrictineacapitisaretrospectivecohortstudyfrom2010to2021
AT renertyuvalyael pediatrictineacapitisaretrospectivecohortstudyfrom2010to2021
AT khamaysiziyad pediatrictineacapitisaretrospectivecohortstudyfrom2010to2021
AT avitanhershemily pediatrictineacapitisaretrospectivecohortstudyfrom2010to2021
AT friedlandrivka pediatrictineacapitisaretrospectivecohortstudyfrom2010to2021